206 related articles for article (PubMed ID: 17592032)
1. Development of cystic glandular hyperplasia of the endometrium in Mullerian inhibitory substance type II receptor-pituitary tumor transforming gene transgenic mice.
El-Naggar SM; Malik MT; Martin A; Moore JP; Proctor M; Hamid T; Kakar SS
J Endocrinol; 2007 Jul; 194(1):179-91. PubMed ID: 17592032
[TBL] [Abstract][Full Text] [Related]
2. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.
Connolly DC; Bao R; Nikitin AY; Stephens KC; Poole TW; Hua X; Harris SS; Vanderhyden BC; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1389-97. PubMed ID: 12649204
[TBL] [Abstract][Full Text] [Related]
3. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
[TBL] [Abstract][Full Text] [Related]
4. Tumorigenic potential of pituitary tumor transforming gene (PTTG) in vivo investigated using a transgenic mouse model, and effects of cross breeding with p53 (+/-) transgenic mice.
Fong MY; Farghaly H; Kakar SS
BMC Cancer; 2012 Nov; 12():532. PubMed ID: 23164239
[TBL] [Abstract][Full Text] [Related]
5. Small interfering RNA against PTTG: a novel therapy for ovarian cancer.
El-Naggar SM; Malik MT; Kakar SS
Int J Oncol; 2007 Jul; 31(1):137-43. PubMed ID: 17549414
[TBL] [Abstract][Full Text] [Related]
6. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update.
Salehi F; Kovacs K; Scheithauer BW; Lloyd RV; Cusimano M
Endocr Relat Cancer; 2008 Sep; 15(3):721-43. PubMed ID: 18753362
[TBL] [Abstract][Full Text] [Related]
7. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
8. Chronic hypersecretion of luteinizing hormone in transgenic mice disrupts both ovarian and pituitary function, with some effects modified by the genetic background.
Nilson JH; Abbud RA; Keri RA; Quirk CC
Recent Prog Horm Res; 2000; 55():69-89; discussion 89-91. PubMed ID: 11036934
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
10. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis.
Heaney AP; Horwitz GA; Wang Z; Singson R; Melmed S
Nat Med; 1999 Nov; 5(11):1317-21. PubMed ID: 10546001
[TBL] [Abstract][Full Text] [Related]
11. High levels of luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin-alpha-subunit promoter/Simian virus 40 T-antigen fusion gene.
Mikola M; Kero J; Nilson JH; Keri RA; Poutanen M; Huhtaniemi I
Oncogene; 2003 May; 22(21):3269-78. PubMed ID: 12761497
[TBL] [Abstract][Full Text] [Related]
12. Pituitary tumor-transforming gene and its binding factor in endocrine cancer.
Smith VE; Franklyn JA; McCabe CJ
Expert Rev Mol Med; 2010 Dec; 12():e38. PubMed ID: 21129230
[TBL] [Abstract][Full Text] [Related]
13. Suppression of lung cancer with siRNA targeting PTTG.
Kakar SS; Malik MT
Int J Oncol; 2006 Aug; 29(2):387-95. PubMed ID: 16820881
[TBL] [Abstract][Full Text] [Related]
14. Ovarian expression of human insulin-like growth factor-I in transgenic mice results in cyst formation.
Dyck MK; Parlow AF; Sénéchal JF; Sirard MA; Pothier F
Mol Reprod Dev; 2001 Jun; 59(2):178-85. PubMed ID: 11389552
[TBL] [Abstract][Full Text] [Related]
15. Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice.
Abbud RA; Takumi I; Barker EM; Ren SG; Chen DY; Wawrowsky K; Melmed S
Mol Endocrinol; 2005 May; 19(5):1383-91. PubMed ID: 15677710
[TBL] [Abstract][Full Text] [Related]
16. Regulation of angiogenesis and invasion by human Pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2).
Malik MT; Kakar SS
Mol Cancer; 2006 Nov; 5():61. PubMed ID: 17096843
[TBL] [Abstract][Full Text] [Related]
17. Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells.
Hamid T; Malik MT; Kakar SS
Mol Cancer; 2005 Jan; 4(1):3. PubMed ID: 15649325
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology of pituitary adenomas.
Donangelo I; Melmed S
J Endocrinol Invest; 2005; 28(11 Suppl International):100-5. PubMed ID: 16625857
[TBL] [Abstract][Full Text] [Related]
19. Murine pituitary tumor-transforming gene functions as a securin protein in insulin-secreting cells.
Yu R; Cruz-Soto M; Li Calzi S; Hui H; Melmed S
J Endocrinol; 2006 Oct; 191(1):45-53. PubMed ID: 17065388
[TBL] [Abstract][Full Text] [Related]
20. A novel molecular marker of pituitary tumor transforming gene involves in a rat liver regeneration.
Akino K; Akita S; Mizuguchi T; Takumi I; Yu R; Wang XY; Rozga J; Demetriou AA; Melmed S; Ohtsuru A; Yamashita S
J Surg Res; 2005 Nov; 129(1):142-6. PubMed ID: 15936773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
